A股異動 | 魯西化工(000830.SZ)續漲逾6% 光大證券給予公司買入評級
格隆匯7月3日丨魯西化工(000830.SZ)繼上交易日大漲6.8%後,於今日至現價8.63元再度上漲6.54%,最新總市值126億。光大證券指,中化入主,迎來新一輪成長重要起點,且資本開支保障和和能源瓶頸問題有望解決。跟蹤發行,公司大部分主營產品自4月份以來盈利水平持續修復向上,上調2020年並維持2021-2022年盈利預測,預計20-22年EPS 分別為0.48、1.05、1.65 元(前次為0.28、1.05、1.65 元),公司與中化集團的融合正式開啟,新一輪成長空間打開,調升至“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.